Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

NCT06931717 2026-03-18

ARCH

Phase 3 Recruiting

390 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06171750 2026-03-06

ANCHOR

Phase 1 Recruiting

97 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Skin Neoplasms

NCT06918132 2026-02-24

N-PLANC

Phase 2 Recruiting

60 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06219317 2026-02-23

ICARS

Phase 2 Recruiting

136 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06465329 2026-02-12

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Recruiting

120 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06731270 2026-02-12

Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

Phase 2 Recruiting

20 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06656598 2026-02-11

SPORADIC

Phase 2 Recruiting

152 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05208944 2026-01-20

THIO Sequenced With Cemiplimab in Advanced NSCLC

Phase 2 Recruiting

227 enrolled

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

NCT06908304 2026-01-12

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

Phase 3 Recruiting

300 enrolled

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

NCT05317858 2025-12-10

LIMITLESS

Phase 3 Recruiting

30 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06917573 2025-11-19

PALACE

Phase 2 Recruiting

63 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT05142189 2025-11-12

LuCa-MERIT-1

Phase 1 Recruiting

280 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06623656 2025-10-23

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

Phase 2 Recruiting

112 enrolled

Thoracic

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT06463665 2025-09-26

VIRO-25

Phase 2 Recruiting

142 enrolled

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Vaccinia

NCT06865339 2025-09-10

TRIPL

Phase 2 Recruiting

76 enrolled

Thoracic

NSCLC

NCT06090266 2025-01-07

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

Phase 1/2 Recruiting

168 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Neoplasms

NCT05501665 2024-10-17

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Phase 1/2 Recruiting

25 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06532149 2024-08-09

EROS

Recruiting

80 enrolled

OtherThoracic

Carcinoma, Non-Small-Cell Lung, Eunuchism, Erectile Dysfunction, Sexual Dysfunction, Physiological

Clinical Trials

CEMI-LUNG

ARCH

ANCHOR

N-PLANC

ICARS

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

SPORADIC

THIO Sequenced With Cemiplimab in Advanced NSCLC

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

LIMITLESS

PALACE

LuCa-MERIT-1

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

VIRO-25

TRIPL

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

EROS